Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PANK3 | Q9H999 | 2/20 | 0.45 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | STAT3 | P40763 | 1/20 | 0.40 |
| ▸ | KCNH2 | Q12809 | 6/20 | 0.40 |
| ▸ | NTRK1 | P04629 | 6/20 | 0.40 |
| ▸ | NTRK2 | Q16620 | 5/20 | 0.40 |
| ▸ | NTRK3 | Q16288 | 4/20 | 0.40 |
| ▸ | GPBAR1 | Q8TDU6 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
| ▸ | MCHR1 | Q99705 | 2/20 | 0.38 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.38 |
| ▸ | RET | P07949 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4977142 | 0.91 | KDM4E (0.45) | HRH3KDM4EALDH1A1MAPTMCHR1 | |
| SCHEMBL4976765 | 0.90 | ENPP2 (0.42) | KDM4EALDH1A1MAPT | |
| SCHEMBL4979742 | 0.89 | ALDH1A1 (0.48) | HRH3KDM4EALDH1A1MAPT | |
| SCHEMBL4974912 | 0.89 | ME2 (0.44) | HRH3KDM4EALDH1A1 | |
| SCHEMBL4977925 | 0.88 | HSP90AB1 (0.48) | PANK3HRH3KDM4EALDH1A1MAPT | |
| SCHEMBL4974609 | 0.87 | KDM4E (0.48) | HRH3KDM4EALDH1A1KCNH2GPR119 | |
| SCHEMBL4973602 | 0.87 | HSP90AB1 (0.49) | HRH3KCNH2 | |
| SCHEMBL4980689 | 0.86 | HSP90AB1 (0.48) | PANK3HRH3KDM4EALDH1A1KCNH2 | |
| SCHEMBL4979654 | 0.86 | MAPT (0.46) | PANK3HRH3KDM4EALDH1A1MAPT | |
| SCHEMBL4978406 | 0.86 | POLB (0.47) | PANK3KDM4EALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080051387-A1 | TETRAHYDROPYRIDO[3,4-D]PYRIMIDINES AND RELATED ANALOGUES | NEUROGEN CORPORATION | 2008-02-28 | — | — | US | disclosed |
| US-20080051387-A1 | TETRAHYDROPYRIDO[3,4-D]PYRIMIDINES AND RELATED ANALOGUES | NEUROGEN CORPORATION | 2008-02-28 | — | — | US | disclosed |
| US-20080051387-A1 | TETRAHYDROPYRIDO[3,4-D]PYRIMIDINES AND RELATED ANALOGUES | NEUROGEN CORPORATION | 2008-02-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080051387-A1 | TETRAHYDROPYRIDO[3,4-D]PYRIMIDINES AND RELATED ANALOGUES | HRH3, HRH4, HRH2 | PANK3 2296/4885HRH3 1/4885KDM4E 1865/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.